Background/Objectives: 15 N]-ureide is used to study the fate of the colonic urea-nitrogen metabolism. During the passage through the gastrointestinal tract, lactose ureide is hydrolysed to glucose ureide, which is absorbed to a limited extent from the small intestine and is excreted urinarily. In the present study, a procedure has been developed to quantify the urinary excretion of glucose- 
Introduction
Lactose ureide labelled with 13 C on the urea moiety has been proposed as a substrate for the determination of orocaecal transit time by (Heine et al., 1995) . Its application is based on the observation that the bond between the urea and sugar moiety in lactose ureide is completely resistant to human digestive processes, yet it is hydrolysed by the intestinal microbiota upon arrival in the colon. The labelled urea generated in this way is rapidly hydrolysed to 13 CO 2 and NH 3 .
On the basis of the same principle, its 15 N-labelled analogue has been applied as a vehicle to introduce a known amount of urea-nitrogen into the colon. The labelled NH 3 can either be used by the colonic microbiota for their own metabolism, which is followed by faecal 15 N-excretion, or it can be absorbed through the colonic wall, and after conversion in the liver to labelled urea, be excreted in the urine (Jackson et al., 1999) (Figure 1 ). In this way, lactose-[ 15 N,
15 N]-ureide can be used to evaluate the fate of the colonic urea-nitrogen metabolism. Using the same molecule, Jackson et al. (2004) demonstrated that bacteriallyderived amino acids from [ 15 N, 15 N]-urea are available for colonic absorption and thus for the host. We have proposed this molecule as a biomarker to evaluate the influence of preand/or probiotic administration on the colonic ammonia metabolism. It has been shown that bacterial activity and/or growth is stimulated upon administration of pre-and/or probiotics, which is reflected in a shift from urinary to faecal 15 N-excretion (De Preter et al., 2004; Geboes et al., 2005) . Several methods have previously been applied to measure the 15 N-enrichement and total nitrogen content in urine and faeces; however, they do not all allow discrimination between the different chemical forms of the marker. Ruemmele et al. (1997) showed that during the passage through the gastrointestinal tract, lactose ureide is converted by b-galactosidase, located in the brush border of the small bowel, to galactose and glucose ureide, and that glucose ureide is absorbed to a limited extent from the small intestine and is excreted urinarily without being further metabolised. The analytical methodology used by Jackson et al. (1999) (Morrison et al., 2001) .
Chemicals. Meso-inositol and n-heptane were supplied by Vel (Leuven, Belgium), whereas acetone was obtained from Chem-Lab NV (Zedelgem, Belgium). NH 2 OH.HCl was purchased from Sigma-Aldrich (St Louis, MO, USA), pyridine and BSTFA-TMCS (99:1) were obtained from Pierce (Rockford, IL, USA).
Sample preparation. The glucose ureide and lactose ureide content was measured by GC-MS (type time-of-flight (TOF)) technology. Therefore, 40 ml internal standard (meso-inositol (100 mg/100 ml)) was added to 960 ml of a standard solution ( ¼ final concentration range of glucose ureide and lactose ureide between 0 and 30 mg/l). This solution was diluted with 3 ml aceton, mixed for 1 min and centrifuged at 3000 rpm for 20 min to deproteinize the samples. Aliquots of 1 ml were evaporated to dryness, and 100 ml oxime reagent (NH 2 OH.HCl in pyridine, 25 mg/l) was added to the sample, mixed for 1 min and heated for 30 min at 80 1C. The reaction was stopped at À20 1C (10 min), and the samples were evaporated under a stream of nitrogen. Derivatisation was accomplished by adding 50 ml of BSTFA þ TMCS (99:1) to the dried samples, thoroughly mixed and heated at 80 1C. After 35 min, samples were cooled down to room temperature. After adding 250 ml pyrogeen-free H 2 O, samples were extracted with 300 ml n-heptane, and 0.5 ml of this solution was analysed on a GC-MS (Interscience, Louvain-la-Neuve, Belgium). The analytical column was a 30 m Â 0.25 mm i.d., 0.25 mm AT5-MS (Alltech Associates, Deerfield, IL, USA). Helium GC grade was used as a carrier gas, with a constant flow of 1.3 ml/min. The oven temperature was programmed to increase from 200 1C (1 min), with 5 1C/min to 270 1C (isothermal for 15 min). Mass spectrometric detection was performed in full scan mode from m/z 35 to m/z 600 at 10 scans/sec. Xcalibur-software (Thermo Fisher Scientific, Bremen, Germany) was used for the automatisation of the GC-TOF-MS and for data acquisition. The results for glucose-ureide and lactose ureide were expressed as percentage of the administered dose recovered in the different urine fractions.
Study design Subjects. A total of 19 healthy volunteers (10 men and 9 women; mean age 22) were included in the study. None of the subjects had a history of gastrointestinal or metabolic disease or previous surgery (apart from appendectomy). The subjects were free of antibiotics or any other medical treatment influencing gut transit or intestinal flora for at least 3 months before the start of the study. The Ethics Committee of the University of Leuven approved the study and all subjects gave informed consent. Samples. All urine was collected in recipients to which neomycin was added for prevention of bacterial growth. After measurement of the volume, samples were taken and stored at À20 1C until analysis. Upon delivery of the faecal samples, all stools collected on the same day were combined, diluted fivefold with sterile pyrogen-free water and homogenized. The homogenate was ultracentrifuged at 25000 g during 120 min (MR22i, Jouan, St-Herblain, France) and the supernatants were subsequently filtered through a 0.2-mm syringe filter (Supor Acrodisc 32, Gelman Sciences, Ann Arbor, MI, USA) in order to discard the ultimate faecal rests and the bacteria. The final filtrate was used for determination. Aliquots were frozen at À20 1C.
For analysis, 960 ml of urine or faecal extract were prepared according to the standard solution to determine the excretion of glucose-[ 
Statistical analysis
Results were expressed as median and interquartile range (IQR). The statistical analysis was performed with SPSS software (SPSS 16.0 for Windows; SPSS, Chicago, IL, USA). Given the low number of subjects in the treatment groups, non-parametric statistical analysis was used. Statistical evaluation of the data was performed by applying the Wilcoxon and Mann-Whitney test. The level for statistical significance was set at Po0.05.
Results

GC-MS analysis
GC-MS analysis of a derivatisation reaction of glucose ureide showed a peak eluting at 11.02 min, which was identified as the internal standard, and a peak at 15.37 min, identified as glucose ureide. Similarly, lactose ureide was found to elute from the column at 24.85 min. A calibration curve was constructed using dilutions ranging from 0-30 mg/l (r 2 ¼ 0.9923). The limit of detection was established at 1.25 mg/l. A good interday and intraday reproducibility was found in the analysis of the urine samples (o10% RSD). 
Discussion
The aim of the present study was to develop an analytical procedure using GC-MS analysis to quantify in a prospective study the urinary excretion of glucose-[ -[ 15 N, 15 N]-ureide V De Preter et al small intestine. We determined previously the orocaecal transit time, that is, the time to reach the colon, of the standard test meal used in the present study and found it to approximate 360 min (Verbeke et al., 2005) . Thus, the time for appearance of the label in urine within the first 6 h, after administration, is due to hydrolysis of lactose- N]-ureide and galactose by the enzyme b-galactosidase, which is located in the brush border of the small intestine, subsequent absorption and distribution in the body, followed by renal excretion. However, also in the 6-9 h and 9-24 h urine collection, a small amount of 15 N-labelled glucose ureide was recovered, suggesting that a 
GC-MS analysis of glucose
